Bcr-aBL1 kinase domain mutation analysis in chronic myeloid leukaemia patients with suboptimal response to tyrosine kinase inhibitors

Background: The acquired mutations in the BCR-ABL1 kinase domain (KD) may contribute to resistance to tyrosine kinase inhibitors (TKIs) in chronic myeloid leukemia (CML) patients. The aim of our work was to perform the BCRABL1 mutation analysis in a cohort of CML patients receiving TKIs, who did...

Full description

Bibliographic Details
Main Authors: Tadej Pajič, Nejc Lamovšek, Martina Fink, Irena Zupan Preložnik, Peter Černelč
Format: Article
Language:English
Published: Slovenian Medical Association 2012-12-01
Series:Zdravniški Vestnik
Online Access:http://vestnik.szd.si/index.php/ZdravVest/article/view/755